Histone H3K36M mutation and trimethylation patterns in chondroblastoma

Area of Science:

• Oncology
• Histopathology
• Molecular Pathology

Background:

• Histones are key chromatin components; mutations, like H3K36M, impact methylation and acetylation, influencing tumorigenesis.
• Chondroblastomas frequently exhibit the H3K36M mutation, a critical factor in their development.
• Histone modifications are increasingly recognized as drivers of various cancers, including bone tumors.

Purpose of the Study:

• To evaluate the diagnostic sensitivity of a novel H3K36M mutation-specific antibody in chondroblastoma.
• To investigate alterations in histone methylation patterns (H3K27me3, H3K36me3) in chondroblastoma.
• To correlate H3K36M expression with histological and clinical features of chondroblastoma.

Main Methods:

• Immunohistochemistry was performed on 27 chondroblastoma samples using antibodies for H3K36M, H3K27me3, H3K36me3, and SATB2.
• Clinical and radiological data from 27 patients were retrospectively reviewed.
• Staining patterns (nuclear, diffuse, focal, heterogeneous) were analyzed for each marker.

Main Results:

• 96% (26/27) of chondroblastomas showed positive nuclear H3K36M immunostaining, often with a diffuse pattern.
• Histone methylation markers H3K27me3 and H3K36me3 displayed heterogeneous staining across all cases, irrespective of mutation status.
• SATB2, an osteoblastic marker, was expressed focally or diffusely in 81% (21/26) of cases.

Conclusions:

• The H3K36M mutation-specific antibody demonstrates high sensitivity for diagnosing chondroblastomas.
• Immunohistochemical detection of H3K36M is a valuable diagnostic tool for chondroblastoma.
• H3K27me3 and H3K36me3 expression patterns are heterogeneous in chondroblastomas, suggesting complex regulatory mechanisms.